Eurofins Scientific

BioPharma's slowdown raises questions on 2026 organic growth target

23/07/26 -"Eurofins’ H1 results were in line with expectations on revenues but ahead of them on adjusted EBITDA. Organic growth improved sequentially with resilient growth in Life and good growth in ..."

PDF page sample
Pages
49
Language
English
Published on
23/07/26
Download
You may also be interested by these reports :
24/07/26
Securitas delivered a disappointing Q2 2026 performance, with no reported organic growth and an operating margin before amortisation slightly below ...
24/07/26
SGS saw organic growth accelerate in Q2 across NR, H&N and C&P, alongside resilient growth in Certification. However, growth in I&E was impacted by ...
23/07/26
Eurofins’ H1 results were in line with expectations on revenues but ahead of them on adjusted EBITDA. Organic growth improved sequentially with ...
22/07/26
Organic revenue growth accelerated in Q2 2026, driven by Operational and Enterprise segments, with growth returning in North America and Germany. ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO